Skip to main content
letter
. 2019 Jul 11;106(7):1988–1990. doi: 10.3324/haematol.2019.223503

Figure 1.

Figure 1.

Flow chart of myelofibrosis patient cohorts and outcomes according to myeloid chimerism and molecular disease status. *These two patients underwent immunosuppression reduction before any evidence of relapse. One was converted to full donor chimerism, and the other had progressive loss of donor myeloid chimerism and graft failure. **This patient with mixed T-cell chimerism had a molecular relapse (recurrent JAK2 mutation) that responded to a tacrolimus dose reduction (converted to full donor chimerism and had molecular remission).